Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
                
   
Misop Han, M.D. Misop Han, M.D.
Associate Professor of Urology
Associate Professor of Oncology

Johns Hopkins Medical Institutions
Director, Urology Residency Program
Director, Urology Informatics

Johns Hopkins Medical Institutions
Physician Advisor, Department of Urology
Johns Hopkins Medical Institutions

Email:mhan1@jhmi.edu
          Discharge Instructions for patients
Dr. Misop Han is an associate professor of urology and oncology at the Johns Hopkins Hospital. Dr. Han is a board-certified urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. When meeting with a patient, Dr. Han carefully reviews the patient's individual situation to determine with the patient the best approach to treatment. 

Dr. Han specializes in:
  1. Prostate Cancer
  2. Robotic Prostatectomy
  3. Robotic Nephrectomy
  4. Nerve-sparing Prostatectomy
  5. Laparoscopic Nephrectomy
  6. Benign Prostatic Hyperplasia (BPH)
  7. Kidney Cancer
Dr. Han received his undergraduate and medical degrees at Johns Hopkins School of Medicine. After an internship in surgery and residencies in surgery and urology, also at Johns Hopkins, he worked as an Assistant Professor of Urology at the Feinberg School of Medicine at Northwestern University and as a urologist at Northwestern Memorial Hospital in Chicago, Illinois. While there, he headed Northwestern University's clinical database for prostate cancer research. In 2006, he joined the Johns Hopkins faculty.

At Johns Hopkins Hospital, Dr. Han is actively involved in researching what happens to men following surgery for prostate cancer.  He has published extensively in these subjects. Click here for his publications.  Click here for the outcome of radical prostatectomy and prediction modeling (Han Tables). Dr. Han's research and clinical trials also involve urologic robotics for image-guided surgery.

Dr. Han has received international and national recognition for his research involving the outcomes of surgeries for patients with prostate cancer. He is a member of the American Urological Association and the American Medical Association, and is certified by the American Board of Urologists.

EDUCATION


1988-1992 B.A. Chemistry
School of Arts and Sciences
Johns Hopkins University, Baltimore, MD
1992-1996 M.D.
School of Medicine
Johns Hopkins University, Baltimore, MD
2003-2005 M.S.
Clinical Investigation
Feinberg School of Medicine
Northwestern University, Chicago, IL

POST-DOCTORAL TRAINING

7/1996-6/1997 Surgical Internship
The Johns Hopkins Hospital
7/1997-6/1998 Surgical Junior Resident
The Johns Hopkins Hospital
7/1998-6/2002 Urology Resident
The James Buchanan Brady Urological Institute
The Johns Hopkins Hospital
7/2002-12/2002 Assistant Chief of Service
The James Buchanan Brady Urological Institute
The Johns Hopkins Hospital

LICENSURE & CERTIFICATION

  • Medical licensures: Maryland and Illinois

  • Specialty Boards: Diplomat of the American Board of Urology

PUBLICATIONS

 Free Access to abstracts at PubMed

  1. North RB, Han M, Zahurak M, Kidd DH: Radiofrequency lumbar facet denervation: analysis of prognostic factors. Pain 1994 Apr;57(1):77-83

  2. Han M, Burnett AL, Fishman EK, Marshall FF: The natural history and treatment of adrenal myelolipoma. J Urol. 1997 Apr;157(4):1213-6

  3. Han M, Schoenberg MP: The use of molecular diagnostics in bladder cancer. Urologic Oncology 2000; 5(3):87-92.

  4. Han M, Nelson JB: Non-steroidal anti-androgens on prostate cancer-current treatment practice. Exp Opin Pharmacother 2000; 1(3):443-449.

  5. Han M, Partin AW, Walsh PC, Rodriguez R: Ability of the 1992 and 1997 American Joint Committee on Cancer (AJCC) staging systems for prostate cancer to predict progression free survival following radical prostatectomy for T2 disease. J Urol. 2000; 164 (1): 89-92.

  6. Han M, Snow PB, Brandt JM, Partin AW: Evaluation of artificial neural networks for the prediction of pathological stage in prostate cancer, Cancer 2001; 91(S8):1661-6.

  7. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC: Isolated local recurrence is rare following radical prostatectomy for men with Gleason 7 diseases and positive surgical margins: Therapeutic implications, J Urol. 2001;165(3):864-6.

  8. Batuello JT, Gamito EJ, Crawford ED, Han M, Partin AW, McLeod DG and O’Connell C: An artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer, Urology 2001; 57(3):481-5.

  9. Han M, Snow PB, Epstein JI, Chan TY, Jones KA, Walsh PC and Partin AW: A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors following radical prostatectomy, Urology 2000; 56(6):994-9.

  10. Han M, Kronz JD, Schoenberg MP: Testicular metastasis of the transitional cell carcinoma of the prostate. J Urol. 2000; 164 (12): 2026.

  11. Han M, Potter SR, Partin AW: The role of free Prostate-Specific Antigen in prostate cancer detection, Current Urology Reports 2000; 1:78-82.

  12. Han M, Piantadosi S, Zahurak ML, Sokoll LJ, Chan DW, Epstein JI, Walsh PC and Partin AW: Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 2001 Apr;57(4):707-11.

  13. Han M, Partin AW, Epstein JI, Walsh PC: Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer, J Urol. 2001 Aug;166(2):416-9.

  14. Han M, Partin AW: The role of ProstaScint scan (111In-capromab pendetide scan), Reviews in Urology 2001; 3 (4):165-71.

  15. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, and Partin AW: Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer, Urology 2001 Nov;58(5):746-51.

  16. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC and Partin AW: Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatctomy. Urology 2001 Jun;57(6):1033-7.

  17. Han M, Partin AW: Nomograms for Clinically Localized Prostate Cancer. Part I. Radical Prostatectomy, Seminars in Urologic Oncology 2002 May; 20 (2): 123-30.

  18. Gretzer MB, Trock BJ, Han M, Walsh PC: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria, J Urol 2002 Oct;168(4 pt 1): 1419-22.

  19. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC: Prediction of biochemical (PSA) recurrence following radical prostatectomy for clinically localized prostate cancer. J Urol 2003 Feb; 169 (2):517-23.

  20. Han M, Partin AW, Chan DY, Walsh PC: An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004 Jan; 171 (1):23-6.

  21. Han M, Nadler RB, Catalona WJ: Point and Counterpoint Debate on the Approaches to Radical Prostatectomy, In Favor of the Traditional Radical Retropubic Prostatectomy (RRP). Contemporary Urology 2004 Feb; 16(2): 38-45.

  22. KHan MA, Han M, Partin AW, Epstein JI, Walsh PC: Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update. Urology 2003 Jul; 62(1): 86-91.

  23. Antenor AV, Han M, Roehl KA, Nadler RB, Catalona WJ: Relation between initial screening PSA level and subsequent prostate cancer detection in a longitudinal screening population. J Urol 2004 Jul; 172(2): 90-93.

  24. Roehl KA, Han M, Ramos CG, Antenor JV, Catalona WJ: Cancer Progression and Survival Rates After Anatomic Radical Retropubic Prostatectomy in 3,478 Consecutive Patients: Long-Term Results. J Urol 2004 Sep; 172 (4): 910-4.

  25. Eggener SE, Roehl KA, Smith ND, Antenor JV, Han M, Catalona WJ: Contemporary Survival Results and the Role of Radiation Therapy in Patients with Seminal Vesicle Invasion Following Radical Prostatectomy. J Urol 2005 Apr; 173 (4): 1150-5.

  26. Antenor JV, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ: Preoperative PSA and Progression-Free Survival Following Radical Prostatectomy for Stage T1c disease. Urology. 2005 Jul;66(1):156-60.

  27. Kundu SD, Roehl KA, Eggener SE, Antenor JV, Han M, Catalona WJ: Potency, Continence and Complications in 3,477 Consecutive Radical Retropubic Prostatectomies. J Urol 2004 Dec; 172 (6):2227-31.

  28. Jang TL, Han M, Catalona WJ: More Favorable Tumor Features and Progression-Free Survival Rates in a Longitudinal Prostate Cancer Screening Study: PSA Era- and Threshold-Specific Effects. Urology (submitted)

  29. Han M, Brannigan RE, Antenor JV, Roehl KA, Catalona WJ: The Association between Hemospermia and Prostate Cancer. J Urol 2004 Dec; 172 (6):2189-92.

  30. Loeb S, Han M, Roehl DA, Antenor JV, Catalona WJ: Accuracy of Prostate Size Estimation by Digital Rectal Examination Versus Transrectal Ultrasonography. J Urol 2005 Jan;173(1):63-5.

  31. Kundu SD, Grubb RL, Roehl KA, Antenor JV, Han M, Catalona WJ: Delays in Cancer Detection Using Two- and Four-Year Screening Intervals for Prostate Cancer Screening with Initial PSA Less than 2 ng/mL. J Urol 2005 Apr; 173 (4):1116-20.

  32. Gonzalez C, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ: Preoperative PSA Level Significantly Associated with Interval to Biochemical Progression After Radical Retropubic Prostatectomy. Urology 2004 Oct, 64 (4):723-8.

  33. Kundu SD, Han M, Catalona WJ: Should an Isolated Humeral Lesion Detected During Prostate Cancer Metastatic Survey be Biopsied? J Urol 2004 Nov;172(5 Pt 1):1825-6.

  34. Loeb S, Gonzalez CM, Han M, Roehl KA, Antenor JAV, Yap R, and Catalona WJ: Does Prostate-Specific Antigen (PSA)- Based Screening Detect Harmless Prostate Cancer?

  35. Han M, Partin AW: Authors’ Reply Letter to the article “An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series.” J Urol. 2005 May;173(5):1828.

  36. Pazona J, Han M, Hawkins SA, Catalona WJ: Salvage Radiation Therapy for PSA Progression Following Radical Prostatectomy: 10-year Outcome Estimates. J Urol. 2005 Oct;174(4 Pt 1):1282-6.

  37. Gann PH, Han M: The Natural History of Clinically Localized Prostate cancer. Editorial. JAMA 2005 May; 293(17): 2149-2151.

  38. Han M, Smith ND, Antenor JAV, Roehl KA, Catalona WJ: Does Transurethral Resection of the Prostate (TURP) Compromise the Subsequent Radical Retropubic Prostatectomy (RRP) Outcomes?. Urology (submitted).

  39. Dale W, Bilir P, Han M, Meltzer D: The role of Anxiety in Prostate Carcinoma. Cancer 2005 June 15.

  40. Han M, Yu X, Gashti SN, Yeh JT, Hawkins SA, Pattison MR, Catalona WJ: Histopathologic Features of Prostate Tumors Detected at Different PSA Levels in the Contemporary PSA Era. (in preparation)

  41. Han M, Pattison MR, Hawkins SA, Yu X, Liao L, Catalona WJ: Prediction of Advance Prostate Cancer Using Biopsy Parameters: The contribution of Tumor Percentage, Volume, and the Number of Positive Biopsy Cores. (in preparation)

  42. Macejko A, Han M, Kozlowski J, Hawkins SA, Antenor JAV, Roehl KA, Yu X, Catalona WJ: Do Most Patients with a PSA-detected Prostate Cancer and a Very Large Prostate Gland have a “Clinically Insignificant” Tumor. (in preparation)


BOOK CHAPTERS
  1. Han M, Polascik TJ: Chapter 5. Urologic procedures. Johns Hopkins Manual of Common Bedside Surgical Procedures. Chen H, Sonnandy C, Lillemoe K. Williams & Wilkins. 1999.

  2. Han M, Schoenberg MP: In vitro testing of bladder tumor. American Urological Association Update Series 2001 Vol XX, Lesson 28, 218-23.

  3. Han M, Partin AW: Chapter IV. Anatomic radical retropubic prostatectomy for prostate cancer. Prostate cancer in the 21st century. Chung L, Isaacs J, Simons J. The Humana Press, Inc. 2001, 377-386.

  4. Han M, Partin AW: The role of free PSA (prostate-specific antigen) and hK-2 (human kallikrein-2) in prostate cancer detection. American Urological Association Update Series 2001.

  5. Han M, Alfert H, Partin AW: Chapter 41, Retropubic and suprapubic open prostatectomy. Campbell’s Urology, 8th edition, Walsh, Retik, Vaughan and Wein. Saunders.

  6. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urologic Clinics of North America 2001 Aug; 29 (3):555-65.

  7. Han M, Catalona WJ: Anatomic Nerve-Sparing Radical Retropubic Prostatectomy. Urologic Oncology 2004, Chapter 29: 514-27.

  8. Han M, Gann PH, Catalona WJ: PSA and Screening for Prostate Cancer. Medical Clinics of North America 2004 Mar; 88(2):245-65.

  9. Han M, Catalona WJ: What Is the Best PSA Prompt for Biopsy? AUA News March 2004; 9(2):30-1.

  10. Han M, Catalona WJ: New Markers for Prostate Cancer. Urologia Contemporânea (in press).

  11. Han M, Catalona WJ: New Markers for Prostate Cancer: Renal and Urology News July/August 2004, 39-40.

  12. Han M, Partin AW: Multivariate Models for Predicting Pathological Stage. Prostate Cancer: Principles and Practice, Kirby, Fenley, Parsons, Partin (in press).

  13. Han M, Catalona WJ: New Concepts in Early Detection of Prostate Cancer. Prostate Cancer: Principles and Practice, Kirby, Fenley, Parsons, Partin (in press).

  14. Han M, Partin AW: Chapter , Retropubic and suprapubic open prostatectomy. Walsh Campbell’s Urology, 9th edition, Wein, Peters, Kavoussi, Partin and Someone. Saunders.

  15. Han M, Catalona WJ: Management of Prostate Cancer. Walsh Campbell’s Urology, 9th edition, Wein, Peters, Kavoussi, Partin and Someone. Saunders.


VIDEOS
  1. Han M, Chan DY, Jackman SV, Fabrizio MF, Kavoussi LR, Jarrett TW: The "Mini-Perc" technique: a less invasive alternative to standard percutaneous nephrolithotomy. Presented at the 94th AUA Annual Meeting, V47, Dallas, TX, May 1999. AUA Video Library HV 2209.


ABSTRACTS
  1. Han M, Snow PB, Chan TY, Epstein JI, Walsh PC, Partin AW: Ability of an artificial neural network to predict progression-free survival for men with Gleason score 3+4 versus Gleason score 4+3 tumors following radical prostatectomy. AUA 2000, Atlanta, GA

  2. Han M, Partin AW, Walsh PC, Rodriguez R: Ability of the 1992 and 1997 American Joint Committee on Cancer (AJCC) staging systems for prostate cancer to predict progression free survival following radical prostatectomy for T2 disease. AUA 2000, Atlanta, GA

  3. Walsh PC, Han M, Pound CR, Epstein JI, Partin AW: Isolated local recurrence is rare following radical prostatectomy for men with Gleason 7 disease who have positive surgical margins: therapeutic implications. AUA 2000, Atlanta, GA

  4. Han M, McCadden J, Rodriguez R: Estrogenic effect of Glucosamine Sulfate/Chondroitin Sulfate. Mid-Atlantic Section AUA 2000, Rio Grande, PR

  5. Han M, Lai S, Partin AW, Epstein JI, Walsh PC: Prediction of biochemical (PSA) recurrence following radical prostatectomy for clinically localized prostate cancer. AUA 2001, Annaheim, CA, Mid-Atlantic Section AUA 2000, Rio Grande, PR

  6. Nielson ME, Han M, Walsh PC, Partin AW: Pathologic outcome and biochemical recurrence in African-American and Caucasian men following radical prostatectomy for clinically localized prostate cancer: Mid-Atlantic Section AUA 2002, Baltimore, MD, AUA 2003, Chicago, IL

  7. Han M, Chan DYC, Partin AW: An evaluation of the decreasing incidence of positive surgical margins in a large radical retropubic prostatectomy series. AUA 2003, Chicago, IL

  8. Han M, Hawkins SA, Catalona WJ: Salvage Radiation Therapy for PSA Progression Following Radical Prostatectomy: 10-year Outcome Estimates. AUA 2004, San Francisco, CA

  9. Han M, Brannigan RE, Catalona WJ: The Association Between Hematospermia and Prostate Cancer. AUA 2004, San Francisco, CA

  10. Han M, Hawkins SA, Catalona WJ: Two Distinct Types of Prostate Cancer Are Detected With Digital Rectal Examination at PSA Levels Below 2.6 ng/mL. AUA 2004, San Francisco, CA

  11. Jang TL, Han M, Catalona WJ: More Favorable Tumor Features and Progression-Free Survival Rates in a Longitudinal Prostate Cancer Screening Study: PSA Era- and Threshold-Specific Effects. AUA 2004, San Francisco, CA

  12. Lee SH, Deaton RJ, Han M, Chow YC, Gann PH: Free PSA and Prediction of Prostate Cancer Among Men Undergoing Repeat Prostate Biopsies. AUA 2004, San Francisco, CA

  13. Han M, Smith ND, Catalona WJ: Does Transurethral Resection of Prostate Compromise the Subsequent Radical Retropubic Prostatectomy Outcomes? AUA 2004, San Francisco, CA

  14. Rubenstein J, Han M, Hawkins SA, Catalona WJ: Adjuvant Radiation Therapy Following Radical Retropubic Prostatectomy for Adverse Pathology. AUA 2004, San Francisco, CA

  15. Williams D, Land S, Han M, Brannigan R: Paternity Rates in the US 1993-2002: Analysis of Birth Rates by Paternal Age and Race. American Society for Reproductive Medicine 2004, Philadelphia, PA

  16. Yang XJ, Han M, Catalona WJ: MHL-1: New Immunohistochemical Marker for Prostate Cancer. AUA 2005, San Antonio, TX

  17. Yu X, Han M, Gashti SN, Yeh JT, Roehl KA, Catalona WJ: Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer. AUA 2005, San Antonio, TX

  18. Gashti SN, Roehl KA, Yu X, Antenor JAV, Yeh JT, Han M, Catalona WJ: Perineural Invasion: Surrogate Marker for the Extent of Cancer in Radical Prostatectomy Specimens. AUA 2005, San Antonio, TX

  19. Macejko A, Han M, Kozlowski J, Hawkins SA, Antenor JAV, Roehl KA, Yu X, Catalona WJ: Do Most Patients with a PSA-detected Prostate Cancer and a Very Large Prostate Gland have a “Clinically Insignificant” Tumor: AUA 2005, San Antonio, TX

  20. Antenor JAV, Roehl KA, Han M, Catalona WJ: PSA Velocity Cutoff for Recommending Biopsy: Positive Predictive Value. AUA 2005, San Antonio, TX

  21. Neilsen ME, Han M, Walsh PC, Partin AW, Freedland SJ: Body Mass Index and Outcomes in African-American and Caucasian Men Following Radical Prostatectomy for Clinically Localized Prostate Cancer. AUA 2005, San Antonio, TX

  22. Han M, Pattison MR, Hawkins SA, Yu X, Bedford DF, Liao L, Catalona WJ: Prediction of Advance Prostate Cancer Using Biopsy Parameters: The contribution of Tumor Percentage, Volume, and the Number of Positive Biopsy Cores. AUA 2005, San Antonio, TX

  23. Catalona, WJ, Yu X, Roehl KA, Yeh JT, Gashti SN, Antenor JAV, Han M: Serum PSA correlates more strongly with Percentage of Cancer and Cancer Volume than with Prostate Size. AUA 2005, San Antonio, TX

  24. Loeb S, Yu X, Roehl KA, Antenor JAV, Yeh JT, Gashti SN, Han M, Catalona WJ: Predicting Adverse Pathology and Cancer Progression: Comparison of Tumor Volume, Perineural Invasion, Percent Cancer and Lymphovascular Invasion in Radical Prostatectomy Specimen. AUA 2005, San Antonio, TX

  25. Eggener SE, Roehl KA, Han M, Catalona WJ: Predictors of Subsequent Prostate Cancer in Men with a PSA Level of 2.6-4.0 ng/mL and An Initially Negative Biopsy. AUA 2005, San Antonio, TX

  26. Han M, Yu X, Gashti SN, Yeh JT, Hawkins SA, Pattison MR, Bedford DF, Catalona WJ: Histopathologic Features of Prostate Tumors Detected at Different PSA Levels in the Contemporary PSA Era. AUA 2005, San Antonio, TX.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

  • American Urological Association

  • American Urological Association, North Central Section

  • American Medical Association

AWARDS & HONORS

1988-1992 Dean's List, School of Arts and Sciences, Johns Hopkins University
  Phi Beta Kappa
  Graduated with General and Departmental Honors
AUA 2000 (ACMI-Circon) resident’s essay contest, clinical research, third prize
AUA 2001 (Astro-Zeneca) resident’s essay contest, clinical research, first prize
"Ability of an artificial neural network predicts progression free survival for men with Gleason score 3+4 versus Gleason score 4+3 tumors following radical prostatectomy."
AUA 2002 (Astro-Zeneca) resident’s essay contest, clinical research, second prize
"Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer"
Mid-Atlantic Section AUA 2000 Resident's essay contest, clinical research, second prize
"Prediction of biochemical (PSA) recurrence following radical prostatectomy for clinically
localized prostate cancer."
5/2002 Praecis scholar in urology, AUA, Chicago, IL
4/2002 Pfizer scholar in urology, Johns Hopkins Hospital
5/2003 Prostate Cancer SPORE career development award,Northwestern Memorial Hospital
10/2003 Northwestern University Clinical Investigator Training Program Scholar (recipient of tuition support through NIH Clinical Research Curriculum Award (K30))

   CONTACT INFORMATION

 

  • Address:
    Marburg 146,
    600 N. Wolfe St.,
    Baltimore, Maryland 21287-2101
  • Appointments: 410-955-6100
  • Office: 410-502-7454
  • Fax: 410-955-0833




© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287